Marco High-Cost Drugs provides payers and insurers with structured information on high-cost drugs and rare diseases: available clinical evidence, eligibility criteria, and comparison with therapeutic alternatives. It supports coverage decisions with updated and auditable data.
Some answers to questions we often receive
Marco High-Cost Drugs includes a synthesis of comparative efficacy evidence and, where available, references to published cost-effectiveness analyses for each drug.
Yes. The database is updated continuously with decisions from FDA, EMA, and other regulatory bodies, ensuring that evaluations are always based on current information.
Marco High-Cost Drugs enables the generation of a structured evidence evaluation in minutes, significantly reducing response times for urgent requests and allowing payers to meet regulatory response deadlines.
Yes. Marco High-Cost Drugs generates traceability of the evaluation process, allowing the payer to document and audit coverage decisions made.
Yes. Marco High-Cost Drugs allows the payer to define and document their own eligibility criteria based on available evidence and aligned with international guideline standards, generating an auditable coverage policy.
Yes. Marco includes comparative information on approved biosimilars for the same indications with therapeutic equivalence evidence, enabling payers to evaluate coverage alternatives with a better cost-effectiveness profile.
Payers receive coverage requests for high-cost drugs for rare diseases and need to evaluate them with scientific rigor and in an auditable way within short timelines.
